Method Validation Of Combinational Drug Substances By Ultra Performance Liquid Chromatography

Article Sidebar

pdf
Published: Dec 16, 2023
DOI: https://doi.org/10.53555/jrtdd.v6i1.2375
Keywords:
Dapagliflozin Metformin Vildagliptin UPLC method validation

Main Article Content

Chowdeswari Darugu
Dr. B. Ananda Kumar
Dr.Ch.S. Anuradha
Dr.S.Shobha Rani

Abstract

Combination drug or a fixed-dose combination (FDC) is a medicine that includes two or more active ingredients combined in a single Dosage form. Dapagliflozin, Metformin and Vildagliptin is a combination of three antidiabetic medicines. Dapagliflozin increases urinary glucose excretion and reduces blood glucose levels. Vildagliptin helps control blood sugar levels by increasing substances (incretins) in the body that make the pancreas release more insulin. An effective stability indicating UPLC method has been developed and validated for the determination of Dapagliflozin, Metformin and Vildagliptin in pure and applied successfully

Article Details

How to Cite
Chowdeswari Darugu, Dr. B. Ananda Kumar, Dr.Ch.S. Anuradha, & Dr.S.Shobha Rani. (2023). Method Validation Of Combinational Drug Substances By Ultra Performance Liquid Chromatography. Journal for ReAttach Therapy and Developmental Diversities, 6(1), 914–921. https://doi.org/10.53555/jrtdd.v6i1.2375
Issue
Vol. 6 No. 1 (2023)
Section
Articles
Author Biographies

Chowdeswari Darugu

Research Scholar, Department of Chemistry, Andhra University TDR-HUB & Assistant Professor in Chemistry, Sir C R Reddy College of Engineering, Eluru

Dr. B. Ananda Kumar

Lecturer, Department of Chemistry, Sri YN College (A), Narsapur - 534275,   West Godavari District, Andhra Pradesh – India

Dr.Ch.S. Anuradha

Lecturer in Chemistry, Dr.V.S.Krishna Government Degree and PG College (A), Visakhapatnam -530013 India

Dr.S.Shobha Rani

Principal, Vishaka Government Degree College for women, Visakhapatnam

References

Collier, Roger (2012). "Reducing the "pill burden"". Canadian Medical Association Journal. 184 (2): E117–E118. doi:10.1503/cmaj.109-4076.

“5-in-1 PolyPill Treatment May Prevent Heart Disease" 2014-02-27 at the Way back Machine, BAYVIEW PHARMACY'S PRESCRIPTION COMPOUNDING BLOG,Apr 01, 2009 @ 08:09 AM.

Combination Products-U.S. Food and Drug Administration.

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Foretz M, Guigas B, Viollet B. Nat Rev Endocrinol. 2019;15:569–589.

Combination therapy for type 2 diabetes: dapagliflozin plus metformin. Tan X, Hu J. Expert Opin Pharmacother. 2016;17:117–126.

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Guarino E, Nigi L, Patti A, Fondelli C, Dotta F. Expert Opin Pharmacother. 2012;13:1377–1384.

Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients. Alsalim W, Persson M, Ahrén B. Diabetes Obes Metab. 2018;20:1652–1658.

Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study. Son C, Makino H, Kasahara M, et al. Diabetes Res Clin Pract. 2021;180:109037.

A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes. Wang LG, Wang H, Liu Q, Hua WC, Li CM. Biomed Pharmacother. 2017;92:707–719